Cargando…

Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors

Virus-based tumour vaccines offer many advantages compared to other antigen-delivering systems. They generate concerted innate and adaptive immune response, and robust CD8(+) T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandasamy, Matheswaran, Gileadi, Uzi, Rijal, Pramila, Tan, Tiong Kit, Lee, Lian N, Chen, Jili, Prota, Gennaro, Klenerman, Paul, Townsend, Alain, Cerundolo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831609/
https://www.ncbi.nlm.nih.gov/pubmed/36626205
http://dx.doi.org/10.7554/eLife.76414
_version_ 1784867880108556288
author Kandasamy, Matheswaran
Gileadi, Uzi
Rijal, Pramila
Tan, Tiong Kit
Lee, Lian N
Chen, Jili
Prota, Gennaro
Klenerman, Paul
Townsend, Alain
Cerundolo, Vincenzo
author_facet Kandasamy, Matheswaran
Gileadi, Uzi
Rijal, Pramila
Tan, Tiong Kit
Lee, Lian N
Chen, Jili
Prota, Gennaro
Klenerman, Paul
Townsend, Alain
Cerundolo, Vincenzo
author_sort Kandasamy, Matheswaran
collection PubMed
description Virus-based tumour vaccines offer many advantages compared to other antigen-delivering systems. They generate concerted innate and adaptive immune response, and robust CD8(+) T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (NY-ESO-1 S-FLU). Intranasal or intramuscular immunization of NY-ESO-1 S-FLU virus in mice elicited a strong NY-ESO-1-specific CD8(+) T cell response in lungs and spleen that resulted in the regression of NY-ESO-1-expressing lung tumour and subcutaneous tumour, respectively. Combined administration with anti-PD-1 antibody, NY-ESO-1 S-FLU virus augmented the tumour protection by reducing the tumour metastasis. We propose that the antigen delivery through S-FLU is highly efficient in inducing antigen-specific CD8(+) T cell response and protection against tumour development in combination with PD-1 blockade.
format Online
Article
Text
id pubmed-9831609
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-98316092023-01-11 Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors Kandasamy, Matheswaran Gileadi, Uzi Rijal, Pramila Tan, Tiong Kit Lee, Lian N Chen, Jili Prota, Gennaro Klenerman, Paul Townsend, Alain Cerundolo, Vincenzo eLife Cancer Biology Virus-based tumour vaccines offer many advantages compared to other antigen-delivering systems. They generate concerted innate and adaptive immune response, and robust CD8(+) T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (NY-ESO-1 S-FLU). Intranasal or intramuscular immunization of NY-ESO-1 S-FLU virus in mice elicited a strong NY-ESO-1-specific CD8(+) T cell response in lungs and spleen that resulted in the regression of NY-ESO-1-expressing lung tumour and subcutaneous tumour, respectively. Combined administration with anti-PD-1 antibody, NY-ESO-1 S-FLU virus augmented the tumour protection by reducing the tumour metastasis. We propose that the antigen delivery through S-FLU is highly efficient in inducing antigen-specific CD8(+) T cell response and protection against tumour development in combination with PD-1 blockade. eLife Sciences Publications, Ltd 2023-01-10 /pmc/articles/PMC9831609/ /pubmed/36626205 http://dx.doi.org/10.7554/eLife.76414 Text en © 2023, Kandasamy et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Cancer Biology
Kandasamy, Matheswaran
Gileadi, Uzi
Rijal, Pramila
Tan, Tiong Kit
Lee, Lian N
Chen, Jili
Prota, Gennaro
Klenerman, Paul
Townsend, Alain
Cerundolo, Vincenzo
Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
title Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
title_full Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
title_fullStr Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
title_full_unstemmed Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
title_short Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
title_sort recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831609/
https://www.ncbi.nlm.nih.gov/pubmed/36626205
http://dx.doi.org/10.7554/eLife.76414
work_keys_str_mv AT kandasamymatheswaran recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT gileadiuzi recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT rijalpramila recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT tantiongkit recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT leeliann recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT chenjili recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT protagennaro recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT klenermanpaul recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT townsendalain recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors
AT cerundolovincenzo recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors